CMPS

#1736
COMPASS Pathways Plc - American Depository Shares
13.0 6 USD
+9.56%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
13.06
13.06
Yıllık Aralık
0.12
13.06
Günlük Değişim
+9.56%
Aylık Değişim
+54.37%
6 Aylık Değişim
+138.32%
Yıllık Değişim
+105.02%
Önceki Kapanış
11.9 2
Open
13.0 6
Düşük
13.0 6
High
13.0 6
Hacim
59
Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler
Çeyreklik Yıllık
  • Market Capitalization 1.76 B
  • Employee 156
  • Founded 2016
  • CEO N/A
  • Website compasspathways.com
  • Headquarter United Kingdom
  • FIGI BBG00X0VY2N1
  • Industry Sağlık Tesisleri
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
-2.24
Fiyat/satışlar oranı
185.88

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

Haberler